Teva Pharmaceutical (TEVA): Assessing Dividend Prospects Amid Balance Sheet Progress
Key Takeaways
- TEVA does not currently pay a dividend, with payments suspended since December 2017 to prioritize debt reduction.
- Strong free cash flow generation of $2.4 billion in 2025 supports ongoing deleveraging, reducing net debt to $13.3 billion.
- Payout ratio is 0% due to no dividend; earnings and cash flow provide ample coverage for potential future resumption.
- TEVA lags peers like VTRS (3.6% yield) and RDY (0.6% yield) in income appeal.
- Improved financial stability may pave the way for shareholder returns, though no timeline announced.
- Suitable for growth-oriented investors, not current income seekers.
Understanding TEVA's Dividend Situation
Teva Pharmaceutical Industries (TEVA), a global leader in generic and innovative medicines, does not pay a dividend. The company suspended dividends in December 2017 amid efforts to strengthen its balance sheet following high debt from past acquisitions. Prior to suspension, TEVA offered quarterly payments, with the last at $0.09 per share (ex-date November 27, 2017). Current dividend yield stands at 0%, and there is no forward dividend or scheduled ex-dividend date. This positions TEVA outside traditional dividend categories like high-yield or growth stocks, focusing instead on reinvestment for operational turnaround. From what I see, investors seeking immediate income should look elsewhere, but TEVA's robust cash generation signals potential for future policy shifts.
A Look at TEVA's Dividend History and Growth
TEVA maintained consistent quarterly dividends for decades, growing modestly from $0.10 per share in 2007 to $0.34 in early 2017. Payments reflected steady increases amid expanding generics dominance. However, financial pressures from the 2016 Actavis Generics acquisition led to a dividend cut to $0.09 in mid-2017 and full suspension by year-end. No payments have occurred since the December 12, 2017 payout. This hiatus aligns with a strategic pivot to growth, emphasizing debt repayment over distributions. Long-term, TEVA's history shows reliability pre-2017, but recent years lack growth or consistency, with no dividend streak or announced resumption plans. One thing that stands out is how this shift has allowed focus on core recovery.
Evaluating Dividend Sustainability and Payout Metrics
With no dividend, TEVA's payout ratio is 0%, fully sustainable by definition. Earnings coverage is strong, with 2025 non-GAAP diluted EPS at $2.93 and revenues of $17.3 billion. Free cash flow (FCF) reached $2.4 billion in 2025, up from prior years, driven by operational efficiencies and working capital optimization. Net debt fell to $13.3 billion from $14.5 billion, with leverage (net debt/EBITDA) at 2.5x, within covenant limits. Guidance for 2026 projects FCF of $2.0-$2.4 billion, primarily allocated to further deleveraging and legal settlements. Debt levels remain elevated but declining, supporting financial stability. In my view, if resumed, a dividend would likely enjoy solid FCF and earnings coverage. I also checked this using Tickeron’s AI Screener to see how TEVA stacks up against industry peers on cash flow metrics.
How TEVA's Dividend Stacks Up Against Peers
In the generic pharmaceuticals sector, TEVA's 0% yield trails competitors. VTRS (Viatris), a key peer formed from Mylan-Upjohn merger, offers ~3.6% yield with $0.48 annual dividend, paid quarterly. RDY (Dr. Reddy's Laboratories) yields ~0.6%, reflecting conservative payout in generics. Broader pharma averages ~1.7%, with high-yielders like PFE (Pfizer) at 6%. TEVA's absence of yield reflects its recovery focus, making it less competitive for income but potentially attractive post-stabilization versus peers balancing returns with growth. This comparison highlights why I'm watching TEVA closely for signs of a turnaround.
Why I Rely on Tickeron's AI Screener
In my research process, Tickeron’s AI Screener has become a go-to tool for efficiently scanning stocks and ETFs across technical patterns, fundamentals, trends, volatility, and AI-driven signals. It lets me filter thousands of names using customizable criteria like industry, market cap, technical indicators, price patterns, and performance metrics—saving hours compared to manual work. Whether hunting dividend payers, income plays, trending names, or breakout opportunities, it uncovers insights in sectors like pharmaceuticals that I might otherwise miss. I use it regularly to refine my watchlist and stay ahead in volatile markets.
Should Dividend Investors Consider TEVA?
TEVA holds limited appeal for traditional dividend investors due to its zero yield and eight-year payment hiatus. Income-focused or conservative investors prioritizing steady quarterly payouts would find better fits in peers like VTRS or branded pharma with reliable histories. However, dividend growth or total return seekers may view TEVA favorably amid its turnaround. Surging FCF ($2.4B in 2025), deleveraging (net debt down to $13.3B), and three years of revenue growth signal improving health. Resuming a modest dividend could attract yield-chasers if management shifts capital allocation post-debt targets. Long-term holders betting on pipeline wins (e.g., Austedo) and generics stabilization might benefit from potential future returns, balancing growth over current income. Risks include ongoing litigation and competition, warranting caution. This is important because it underscores TEVA's fit for growth-oriented portfolios rather than income ones.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TEVA turns positive, indicating new upward trend
TEVA saw its Momentum Indicator move above the 0 level on October 07, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In 61 of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in 225 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 193 of 269 cases where TEVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 59 cases where TEVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for TEVA turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 32 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
TEVA broke above its upper Bollinger Band on September 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.848) is normal, around the industry mean (43.873). P/E Ratio (64.800) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients
Industry PharmaceuticalsGeneric
Advertisement